Please see below for a selection of interesting articles on pediatric CML in peer-reviewed journals.
Latest publications include:

• Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia
  Shima H et al. Pediatr Blood Cancer, April 2022 (epub ahead of print)
• Prognostic factors for outcomes of allogeneic HSCT for children and adolescents/young adults with CML in the TKI era
  Shimada H et al. Transplant Cell Ther, April 2022 (epub ahead of print)
• Skin and soft tissue infections in adolescent chronic myeloid leukemia under dasatinib treatment
  Uchida E et al. Pediatr Blood Cancer, April 2022 (epub ahead of print)
• Therapeutic leukapharesis in pediatric leukemia: Utilization trend and early outcomes in a US Nationwide Cohort
  Takahashi T et cl. J Pediatr Hematol Oncol, March 2022
• Design and stability of pediatric oral formulation of imatinib
  Hinterlang M et al. J Oncol Pharm Pract, March 2022
• Health-related quality of life in children with chronic myeloid leukemia in the chronic phase
  (Zheng F et al. J Cancer Res Clin Oncol, February 2022)
• Comparison of the transcriptomic signature in pediatric and adult CML
  Youn M et al. Cancers(Basel), December 2021 – open access publication
• Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML
  Smith SM et al. Pediatr Hematol Oncol, December 2021 (epub ahead of print)
• Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase
  Lee JW et al. Blood Res, November 2021 (epub ahead of print) – open access publication

Search here for more publications on pediatric CML